PROGYNY, INC. (PGNY): Price and Financial Metrics
Today's Latest Price: $50.24 USD
Jan 22 4:15pm Add PGNY to Watchlist Sign Up
PGNY Stock Summary PGNY's went public 1.25 years ago, making it older than just 0.8% of listed US stocks we're tracking. With a price/earnings ratio of 1,360.15, Progyny Inc P/E ratio is greater than that of about 99.07% of stocks in our set with positive earnings. The ratio of debt to operating expenses for Progyny Inc is higher than it is for about merely 0.53% of US stocks. If you're looking for stocks that are quantitatively similar to Progyny Inc, a group of peers worth examining would be CDAY, FRPT, SGH, KAMN, and CELH. PGNY's SEC filings can be seen here. And to visit Progyny Inc's official web site, go to www.progyny.com.
PGNY Price/Volume Stats
PROGYNY, INC. (PGNY) Company Bio
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
PGNY Latest News Stream
All News Types
Loading, please wait...
Latest PGNY News From Around the Web
Below are the latest news stories about Progyny Inc that investors may wish to consider to help them evaluate PGNY as an investment opportunity.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family…
In the midst of COVID, healthcare companies saw their stocks shoot up in 2020. Companies like Health Catalyst, Progyny and Guardant all saw big increases this year by Steven Loeb on December 29, 2020
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
Progyny CEO David Schlanger joins Yahoo Finance Live to discuss how his company has handled COVID-19, and the future of fertility treatments.
Read More 'PGNY' Stories Here
PGNY Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.762 seconds.